1. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569–74.
2. Hayes-Lattin B, Maziarz RT. Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. Leuk Lymphoma 2004; 45: 669–80.
3. Климко Н.Н., Веселов А.В. Новые препараты для лечения инвазивных микозов. Клинич. микробиол. и антимикроб. химиотер. 2003; 5: 342–53.
4. Dodds Ashley E, Alexander B. Posaconazole. Drugs Today 2005; 41 (6): 393–400.
5. Groll A, Walsh T. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005; 3 (4): 467–87.
6. Boucher H, Groll A, Chiou C et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64 (18): 1997–2020.
7. Andes D, Marchillo K, Conklin R et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48 (1): 137–42.
8. Pfaller M, Messer S, Hollis R et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46 (4): 1032–7.
9. Sabatelli F, Patel R, Mann P et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50 (6): 2009–15.
10. Torres-Narbona M, Guinea J, Martinez-Alarcon J et al. In Vitro Activities of Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole against 45 Clinical Isolates of Zygomycetes: Comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother 2007; 51 (3): 1126–9.
11. Torres H, Hachem R, Chemaly R et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5 (12): 775–85.
12. Courtney R, Pai S, Laughlin M et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47 (9): 2788–95.
13. Conte JR, Golden JA, Krishna G et al. Intra pulmonary ppharmacokinetics-pharmacodynamics of posaconazole. 3 Advancer Against Aspergillosis. 2008.
14. Krieter P, Flannery B, Musick T et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48 (9): 3543–51.
15. Wexler D, Courtney R, Richards W et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21 (5): 645–53.
16. Sansone-Parsons A, Krishna G, Simon J et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007; 51 (2): 495–502.
17. Naggapan V, Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin infect Dis 2007; 45: 1610–7.
18. Ullmann A, Cornely O, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50 (2): 658–66.
19. Krishna G, Sansone-Parsons A, Martinho M et al. Posaconazole Plasma Concentrations in Juvenile Patients With Invasive Fungal Infection. Antimicrob Agents Chemother 2007; 51 (3): 812–8.
20. Antachopoulos C, Walsh T. New agents for invasive mycoses in children. Curr Opin Pediatr 2005; 17 (1): 78–87.
21. Keating G. Posaconazole. Drugs. 2005 65 (11): 1553–67.
22. Pitisuttithum P, Negroni R, Graybill J et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56 (4): 745–55.
23. Tobon A, Arango M, Fernandez D et al. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. CID. 20031; 36 (11): 1488–91.
24. Greenberg R, Mullane K, van Burik J et al. Posaconazole as salvage therapy for Zygomycosis. Antimicrob Agents Chemother 2006; 50 (1): 126–33.
25. van Burik J, Hare R, Solomon H et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. CID 2006; 42 (7): 61–5.
26. Rutar T, Cockerham K. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am J Ophthalmol 2006; 142 (1): 187–8.
27. Page R, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy 2007; 27 (2): 290–8.
28. Walsh T, Raad I, Patterson T et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. CID 2007; 44 (1): 2–12.
29. Raad I, Hachem R, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. CID. 2006; 42 (10): 1398–403.
30. Tu E, McCartney D, Beatty R et al. Successful Treatment of Resistant Ocular Fusariosis With Posaconazole (SCH-56592). Am J Ophthalmol 2007; 143 (2): 222–7.
31. Restrepo A,Tobon A, Clark B et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54 (4): 319–27.
32. Ullmann A, Cornely O. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006; 19 (6): 571–6.
33. Barchiesi F, Spreghini E, Santinelli A et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 2007; 51 (1): 73–7.
34. Cornely O, Maertens J, Winston D et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356 (4): 348–59.
35. Ullmann A, Lipton J, Vesole D et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356 (4): 335–47.
36. Notheis G, Tarani L, Costantino F et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006; 1: 37–41.
37. De Decker K, Van Poucke S, Wojciechowski M et al. Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis. Pediatr Crit Care Med 2006; 7 (5): 482–5.
38. Sorensen J, Becker M, Porto L et al. Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia. Mycoses 2006; 49: 31–6.
39. Chan Y, Goldwater P, Saxon B. Successful treatment of cutaneous and subcutaneous zygomycosis in an immunosuppressed patient with aplastic anaemia. J Paediatr Child Health 2007; 43 (1-2): 87–9.
40. Raad I, Graybill J, Bustamante A et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. CID 2006; 42 (12): 1726–34.
41. Paugam A. The latest data on posaconazole. Med Mal Infect 2007; 54 (4): 319–27.
42. Walsh TJ et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Disieases Society of America. Clin Infect Dis 2008; 46: 327–60.
43. NCCN Clinical Practice Guidelines in Oncology. 2007; 1. Prevention and Treatment of Cancer-Related Infections. www.nccn.org.
44. Maertens JA et al. Primary antifungal prophylaxis in leukemia patients. Eur J Cancer 2007; 5: 43–9.
45. НОКСАФИЛ – Инструкция по медицинскому применению препарата. 2007.